Compare AUID & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | ITRM |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 24.3M |
| IPO Year | 2014 | 2018 |
| Metric | AUID | ITRM |
|---|---|---|
| Price | $1.82 | $0.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 387.9K | ★ 659.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $886,485.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 365.86 | N/A |
| 52 Week Low | $0.84 | $0.20 |
| 52 Week High | $9.44 | $1.49 |
| Indicator | AUID | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 31.75 |
| Support Level | $1.19 | N/A |
| Resistance Level | $1.94 | $0.39 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 98.35 | 7.85 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.